Utilization of Transanal Endoscopy in the Treatment of Anastomotic Stenosis

September 11, 2023 updated by: Yanhong Deng, Sun Yat-sen University

A Prospective Clinical Study of Transanal and Transabdominal Combined Endoscopic Resection of Rectal Stenosis and Anal Reconstruction for Severe Rectal Anastomotic Stenosis

Severe rectal anastomotic stenosis can not only cause intestinal obstruction, but also be accompanied by frequent defecation, which affects the quality of life, and patients face the outcome of permanent stoma or temporary stoma again. Traditional transabdominal resection and reconstruction of rectal anastomotic stenosis is more likely to occur due to unclear anatomical structure, dense scars around the intestinal canal, complications such as ureteral and urethral injury and massive presacral hemorrhage. In addition,41%of patients with anastomotic stenosis who underwent reoperation through abdominal surgery had anastomotic leakage again, and up to 30% of patients could not close the stoma. The advantages of transanal total mesorectal excision (taTME) using a transanal approach for total mesorectal excision in the treatment of middle and low rectal cancer with difficult pelvis have been demonstrated by our group. However, taTME has rarely been explored in the treatment of anastomotic stenosis. Our team retrospectively summarized the patients who underwent transabdominal transanal endoscopic resection and reconstruction of anastomotic stenosis (l-taTME), and initially demonstrated the safety and effectiveness of this surgical method, with a stoma closure rate of 90%. Although the advantages of l-taTME in the treatment of severe rectal anastomotic stenosis are obvious in theory and preliminary clinical practice, there is a lack of prospective studies. Therefore, the investigators plan to conduct a prospective clinical study to observe the safety and efficacy of l-taTME reconstruction surgery, and to provide high-level evidence-based medical basis for the selection of resection and reconstruction surgery for patients with rectal anastomotic stenosis.

Study Overview

Detailed Description

Colorectal cancer is the most common malignant tumor of the digestive tract. At present, surgery is still the main treatment for rectal cancer. Although stapler anastomosis improves the safety of surgical resection and reconstruction for middle and low rectal cancer, surgical complications, especially anastomotic leakage, are inevitable, especially for middle and low rectal cancer, where the incidence of anastomotic leakage reaches 8-11%. The outcome of anastomotic leakage will lead to anastomotic stenosis, especially in middle and low rectal cancer after neoadjuvant radiotherapy, and the incidence of anastomotic stenosis is as high as 3%-10%. Previous studies have suggested that anastomotic diameter < 20mm is considered as an anastomotic stenosis, and it has also been shown that an anastomotic diameter less than 1/3 of the original diameter of the intestinal lumen is considered as an anastomotic stenosis. Anastomotic stenosis can not only cause intestinal obstruction symptoms, such as abdominal distension and abdominal pain, but also be accompanied by frequent defecation, which affects the quality of life, and many patients face the outcome of permanent stoma or temporary stoma again.

Anastomotic stenosis is divided into membranous stenosis and tubular stenosis according to the degree of stenosis. For anastomotic membranous stenosis, endoscopic incision of the stenosis ring or balloon dilatation is the preferred method for the treatment of membranous stenosis. However, endoscopic scar incision and balloon dilation require repeated, multiple treatments to achieve long-term effectiveness, with the risk of perforation, pelvic infection, and bleeding. Balloon dilatation or scar incision has little effect on patients with low anastomosis position or tubular stenosis, and nearly 30% of patients need to undergo resection and reconstruction of the stenotic anastomosis. As anastomotic stenosis is often caused by anastomotic leakage, anastomotic ischemia, radiotherapy and chemotherapy, use of stapler, pelvic infection and low anastomosis, the anatomical structure is unclear, the scar around the bowel is dense, and complications such as ureteral and urethral injury and massive bleeding of presacral veins are more likely to occur during the resection and reconstruction of the stricture. Lefevre et al. reported 33 patients who underwent resection and reconstruction of transabdominal rectal anastomotic stenosis, and the incidence of perioperative complications was 54.5%, including anastomotic leakage of 18%(6/33) and postoperative intestinal obstruction of 12%. Genser et al. reported 50 patients with surgical treatment of anastomotic stenosis, of whom 12(24%) received intraoperative blood transfusion, with an average blood transfusion volume of 2.5 units. The incidence of intraoperative complications was 12%, including 5 cases of bladder injury and 1 case of splenectomy due to splenic injury due to unclear anatomical location. Westerduin et al. summarized 59 patients who underwent secondary surgery for anastomotic leakage and stenosis, and 41% of them had recurrent anastomotic leakage 14 months after surgery. During the follow-up of 27 months, only 66% of the patients regained intestinal continuity,24%of the patients received permanent colostomy, and 10% of the patients retained ileostomy.

Due to the difficulty of surgery, it is difficult to remove the scar tissue around the anastomosis in the traditional abdominal resection and reconstruction surgery. The new rectorectum cannot be pulled out and anastomosed with the distal rectoanal canal again. After reluctant anastomosis, the incidence of anastomotic leakage is still high due to the high tension of rectorectum, and many patients have to accept permanent stoma. Transanal total mesorectal excision (taTME), which uses a transanal approach to perform total mesorectal excision, has been demonstrated by our team for the surgical treatment of middle and low rectal cancer with difficult pelvis. However, the use of taTME in the treatment of anastomotic stenosis is rarely explored at present. Our team first reported this surgical method in 2021. The investigators retrospectively summarized 17 patients who underwent resection and reconstruction of anastomotic stenosis by transabdominal transanal endoscopic surgery. The ileostomy or colostomy was closed in 15 patients, which proved the safety and effectiveness of this surgical method. Transabdominal transanal endoscopic resection and reconstruction surgery has obvious advantages in the treatment of patients with rectal anastomotic stenosis. First, it can accurately separate the narrow distal intestine, and transanal anastomosis of the substitute rectum and the distal rectoanal canal can be performed, which reduces the difficulty of reconstruction. Secondly, from the distal normal anorectal canal, it can enter the normal anatomical structure space, and the narrow scar segment can be completely resected by endoscopic magnification. At the same time, it can reduce the accidental injury of the surrounding normal tissue and significantly reduce the incidence of intraoperative complications. Finally, the mobilization of the left hemicolon and splenic flexure of the abdomen was completed laparoscopically, and the specimen was removed through the anus, which did not require additional abdominal incision and thus reduced trauma. Although the advantages of transanal transabdominal combined with laparoscopic resection and reconstruction in the treatment of severe rectal anastomotic stenosis are very obvious in theory and preliminary clinical practice, there is a lack of prospective studies.

For the above reasons, the investigators plan to conduct a prospective clinical study to observe the safety and efficacy of transanal laparoscopic resection and reconstruction in patients with rectal anastomotic stenosis, in order to improve the quality of life of patients with rectal anastomotic stenosis, and to provide high-level evidence-based medical basis for the selection of resection and reconstruction surgery for patients with rectal anastomotic stenosis.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China
        • Recruiting
        • Sixth Affiliated Hospital of Sun Yat-sen University
        • Contact:
          • Liang Huang, Doctor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age of 18-70 years old;
  2. ECOG performance status score 0-2;
  3. previous rectal resection;
  4. patients diagnosed with middle and low rectal anastomotic tubular stenosis;
  5. can tolerate general anesthesia;
  6. The subjects and their family members, who could understand the study protocol and were willing to participate, signed the informed consent form.

Exclusion Criteria:

  1. patients with acute intestinal obstruction, intestinal perforation or intestinal bleeding requiring emergency surgery;
  2. severe pelvic adhesion and frozen pelvis;
  3. patients with unstable primary tumors or combined with tumors at other sites;
  4. previous history of left hemicolectomy;
  5. ASA grade IV to V;
  6. combined organ resection;
  7. severe mental illness;
  8. pregnant or lactating women;
  9. severe cardiovascular disease, uncontrolled infection or other uncontrolled comorbidities;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patients with severe rectal anastomotic stenosis
Focusing on Patients with severe rectal anastomotic stenosis, espically long length and ultra lower firbrotic stenosis
Laparoscopic or open surgery was selected according to the patient's condition, surgical history and surgeon's experience.According to the extent of the rectal stenosis, the proximal colon was dissected.A circular incision was made above the dentate line and the broken end was sutured. After the intestinal cavity was closed, a single port was inserted through the anus, and a transanal endoscopic platform was established after pneumoperitoneum infusion.The stenotic and scar segments were removed free upward.Through the pelvic cavity and into the abdominal cavity from the bottom up. The narrow rectum and proximal colon were pulled out of the anus through the anus, and the diseased bowel was removed. According to the distance of the remaining distal rectum, stapler or manual anastomosis or Bacon operation was selected.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stoma recovery rate
Time Frame: 3 months after surgery
whether the stoma recovery and restoration of bowel continuation
3 months after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
incidence of postoperative anastomotic leakage
Time Frame: 1 month after surgery
whether the occurence of anastomotic leakage
1 month after surgery
incidence of postoperative anastomotic bleeding
Time Frame: Duration of 7 days after surgery
whether the occurence of anastomotic bleeding
Duration of 7 days after surgery
Incidence of severe bowel dysfunction
Time Frame: 3 months after stoma recovery
Low Anterior Resection Syndrome Score (0-20: No LARS 21-29: Minor LARS 30-42: Major LARS)
3 months after stoma recovery
Incidence of severe bowel dysfunction
Time Frame: 6 months after stoma recovery
Low Anterior Resection Syndrome Score (0-20: No LARS 21-29: Minor LARS 30-42: Major LARS)
6 months after stoma recovery
Incidence of severe bowel dysfunction
Time Frame: 1 year after stoma recovery
Low Anterior Resection Syndrome Score (0-20: No LARS 21-29: Minor LARS 30-42: Major LARS)
1 year after stoma recovery
Incidence of severe bowel dysfunction
Time Frame: 2 years after stoma recovery
Low Anterior Resection Syndrome Score (0-20: No LARS 21-29: Minor LARS 30-42: Major LARS)
2 years after stoma recovery
Anorectal function
Time Frame: 1 year after stoma recovery
Anorectal pressure Rectal sensory function Rectoanal reflex function
1 year after stoma recovery
Anorectal function
Time Frame: 2 year after stoma recovery
Anorectal pressure Rectal sensory function Rectoanal reflex function
2 year after stoma recovery
bowel function
Time Frame: 3 months after stoma recovery
Memorial Sloan-Kettering Cancer Center bowel function instrument
3 months after stoma recovery
bowel function
Time Frame: 6 months after stoma recovery
Memorial Sloan-Kettering Cancer Center bowel function instrument
6 months after stoma recovery
bowel function
Time Frame: 1 year after stoma recovery
Memorial Sloan-Kettering Cancer Center bowel function instrument
1 year after stoma recovery
bowel function
Time Frame: 2 year after stoma recovery
Memorial Sloan-Kettering Cancer Center bowel function instrument
2 year after stoma recovery
Quality of life evaluation after stoma closure
Time Frame: 3 months
European Organization for Research and Treatment of Cancer QLQ-C30 (0-100 0:poor 100:best)
3 months
Quality of life evaluation after stoma closure
Time Frame: 6 months
European Organization for Research and Treatment of Cancer QLQ-C30 (0-100 0:poor 100:best)
6 months
Quality of life evaluation after stoma closure
Time Frame: 1 year
European Organization for Research and Treatment of Cancer QLQ-C30 (0-100 0:poor 100:best)
1 year
Quality of life evaluation after stoma closure
Time Frame: 2 years
European Organization for Research and Treatment of Cancer QLQ-C30 (0-100 0:poor 100:best)
2 years
Quality of life evaluation after stoma closure
Time Frame: 3 years
European Organization for Research and Treatment of Cancer QLQ-C30 (0-100 0:poor 100:best)
3 years
Inraoperative condition
Time Frame: In the process of operation
operation time and whether to convert to laparotomy
In the process of operation
Perioperative recovery time
Time Frame: perioperative period
Duration of analgesics in hours For the first time the exhaust time in hours Time to first defecation in hours Time to first fluid intake in hours Time to resume normal diet in hours Abdominal drainage tube removal time in days Catheter removal time in days Length of postoperative hospital stay in days
perioperative period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yanhong Deng, Doctor, Sun Yat-sen University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2023

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

August 10, 2023

First Submitted That Met QC Criteria

September 11, 2023

First Posted (Actual)

September 14, 2023

Study Record Updates

Last Update Posted (Actual)

September 14, 2023

Last Update Submitted That Met QC Criteria

September 11, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • GIHSYSU-TLCAS

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anastomotic Stenosis

Clinical Trials on Transanal and transabdominal combined endoscopic resection of rectal stenosis and anal reconstruction

3
Subscribe